Single shot, long term male contraception in the offing

Image
Press Trust of India Washington
Last Updated : Mar 30 2016 | 3:28 PM IST
A new single injection male contraceptive may provide rapid, durable and potentially reversible birth control for about a year without the need for condoms, a new study has claimed, ahead of its first human clinical trial this year.
Men currently have few options for reproductive control, including condoms and vasectomy.
While condoms are widely available and useful in preventing disease when used correctly, they have an 18 per cent yearly pregnancy rate in typical use.
Vasectomy is effective, but must generally be considered permanent. There are no long-acting, reversible contraceptives currently available for men.
The new study in rabbits has confirmed that Vasalgel has the potential to fill the gap in male contraception availability.
It consists of styrene-alt-maleic acid (SMA) dissolved in dimethyl sulfoxide and could be the first long-acting, non-hormonal, potentially reversible male contraceptive to reach market, researchers said.
"Results from our study in rabbits were even better than expected. Vasalgel produces a very rapid contraceptive effect which lasted throughout the study due to its unique hydrogel properties," said Dr Donald Waller, Professor of Pharmacology and Toxicology at the University of Illinois at Chicago.
"These features are important considerations for a contraceptive product to be used in humans," said Waller, lead author of the research published in the journal Basic and Clinical Andrology.
The study provided evidence for Vasalgel's value as an effective male contraceptive. The study tested two different formulations of the test article having either 100 per cent SMA acid or 80 per cent SMA acid/20 per cent SMA anhydride.
After the gel was injected into the vas deferens of 12 rabbits, semen analysis showed that 11 rabbits were azoospermic in all samples, having no quantifiable sperm in their semen at all.
One rabbit had a few samples with very small numbers of sperm before also becoming azoospermic. Both test articles were equally effective.
The study also confirmed that the contraceptive effect was durable over the 12 month study period. The response of the vasa deferentia tissue was minimal with characteristics of a normal foreign body response.
The implant remains in a soft gel-like state, with the ability to flex and adhere to walls of the vasa deferentia.
Hydrogels allow transit of many water-soluble molecules but not larger structures such as spermatozoa.
The ability to remove the gel to return the flow of sperm - or reverse the contraceptive effect - was successfully accomplished in the rabbit model, researchers said.
Seven rabbits had the test article flushed from their vas deferens, and semen samples showed a rapid return of sperm flow, they said.
The success of the studies has paved the way for the first clinical trial in men, scheduled to launch late this year, researchers said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 30 2016 | 3:28 PM IST

Next Story